Core Viewpoint - Taimei Medical Technology (02576.HK) announced the approval of the proposed 2026 H-share incentive plan by its board of directors on January 22, 2026, which is subject to shareholder approval at a special general meeting [1] Group 1 - The 2026 H-share incentive plan is regulated under Chapter 17 of the listing rules and must comply with its provisions [1] - The board resolved to grant a total of 20.04 million awards to 63 participants as the initial grant under the 2026 H-share incentive plan [1] - The initial grant will only be finalized upon the adoption of the 2026 H-share incentive plan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任 何 損 失 承 擔 任 何 責 任。 Zhejiang Taimei Medical Technology Co., Ltd. 浙江太美醫療科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：2576） 建議採納2026年H股獎勵計劃 及 建議首次授予 建議採納2026年H股獎勵計劃 於2026年1月22日，董 事 會 已 決 議 批 准 建議採納2026年H股 獎 勵 計 劃。 2026年H股獎勵計劃仍有待股東於 臨時股東會 上 審 議 及 批 准。2026年H 股獎勵計劃受上市規則 第17章 規 管，因 此 將 須 遵 守 上 市 規 則 第17章 的 規 定。2026年H股 獎 勵 計 劃 的 主 要 條 款 載 列 如 下。 建議首次授予 於2026年1月22日，董 事 會 決 議 根 據2026年H股 ...

Core Insights - The company, Taimei Medical Technology, has recently achieved significant milestones, including the global approval of the first load ultrasound echocardiography indication and the first domestic tumor electric field therapy device, bringing the total number of approved projects to 58 across various medical fields [1][2]. Group 1: Project Approvals and Recognition - The IRC team at Taimei Medical Technology has received high recognition from clients for their professionalism and rigorous approach during clinical trials, ensuring accuracy and reliability in evaluation results [2]. - The increasing number of approved projects reflects the company's strong capabilities in navigating regulatory requirements and maintaining high standards in clinical research [1][2]. Group 2: Regulatory Inspection and Compliance - The National Medical Products Administration (NMPA) has raised its inspection standards, focusing on critical aspects that affect the accuracy and independence of image assessments [3][4]. - The eImage system developed by Taimei Medical Technology is highlighted as a crucial tool for meeting these regulatory demands, providing comprehensive tracking and evidence during inspections [3]. Group 3: Inspection Process and Best Practices - The inspection process involves notifying sponsors, executing on-site inspections, and summarizing findings, which requires thorough preparation and documentation [4][5]. - Key areas of focus during inspections include the traceability of case evaluations and adherence to imaging-related protocols [6][7]. Group 4: Team Expertise and Service Strength - The IRC team boasts a strong professional background, with 100% of imaging quality control personnel having medical imaging expertise and all efficacy evaluators holding medical qualifications [8]. - Taimei Medical Technology has established a comprehensive service system, with over 500 project experiences, positioning itself as a reliable partner in the pharmaceutical innovation journey [8].

| 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 363,186,467 RMB | | 1 | RMB | | 363,186,467 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 363,186,467 RMB | | 1 | RMB | | 363,186,467 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 浙江太美醫療科技股份有限公司 (「本公司」) 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 ...

Core Viewpoint - Taimei Medical Technology (02576.HK) has announced the establishment of a partnership agreement involving multiple limited partners and a general partner, with a total initial investment of RMB 227.27 million aimed at prioritizing investments in the Jiaxing Economic and Technological Development Zone [1] Group 1: Partnership Agreement - The partnership agreement was signed on December 24, 2025, after trading hours [1] - The partners include Taimei Medical Technology, Taimei Zhiyan, Jiaxing Chantuo, and several individuals, with varying investment amounts [1] - The total initial investment from all partners amounts to RMB 227.27 million, with specific contributions from each partner detailed [1] Group 2: Investment Details - Taimei Medical Technology will contribute RMB 70 million, while Taimei Zhiyan will invest RMB 30 million [1] - Jiaxing Chantuo is set to invest RMB 100 million, and individual partners will contribute amounts ranging from RMB 2.27 million to RMB 10 million [1] - The partnership will focus on investments in companies located in the Jiaxing Economic and Technological Development Zone [1]

Group 1 - The company, along with several partners, has established a partnership agreement to form a new enterprise with an initial investment of RMB 227.27 million [1] - The investment contributions from the partners include RMB 70 million from the company, RMB 30 million from Taimei Zhiyan, RMB 100 million from Jiaxing Chantuo, and smaller amounts from individual partners [1] - The partnership will prioritize investments in companies located in the Jiaxing Economic and Technological Development Zone [1] Group 2 - The board believes that the establishment of the partnership will enable deep participation in the research and development of innovative drug pipelines, allowing the company to standardize and modularize its digital pharmaceutical R&D solutions [2] - The partnership will hold pipeline rights and participate in early clinical trials, aiming to capture key segments of the industry value chain while avoiding the complexities and long-term risks associated with traditional equity investments [2] - The company anticipates efficient exits through the transfer or sale of pipeline rights, facilitating rapid capital turnover and value realization [2]

董事会相信，通过成立合伙企业公司可以深度参与创新药管线研究及开发，公司将能够将其数智化医药 研发解决方案标准化、模块化地输出给各个处于早期至成长阶段的创新药研发管线，从而有机会分享药 物研发成功的超额收益以及扩大公司的行业足迹；其次，通过合伙企业持有管线权益，参与早期临床试 验抢占行业价值链关键环节，避免传统股权投资的复杂性与长周期风险，通过转让或出售管线实现高效 退出，实现了资金的快速周转和价值兑现。 格隆汇12月24日丨太美医疗科技(02576.HK)公告，于2025年12月24日，公司(作为有限合伙人)、太美智 研(作为有限合伙人)、嘉兴产投(作为有限合伙人)、陆高峰(作为有限合伙人)、陆海啸(作为有限合伙 人)、陈国娟(作为有限合伙人)及凯风太美(作为普通合伙人)订立合伙企业协议，内容有关成立合伙企 业。所有合伙人向合伙企业的初始注资总额将为人民币22,727万元，其中公司、太美智研、嘉兴产投、 陆高峰、陆海啸、陈国娟、及凯风太美将分别注资人民币7,000万元、人民币3,000万元、人民币10,000 万元、人民币1,000万元、人民币500万元、人民币1,000万元及人民币227万元。 合伙企业的业 ...

Group 1 - The company, Taimei Medical Technology, has established a partnership agreement to form a partnership enterprise with an initial total investment of RMB 227.27 million from various partners [1] - The investment contributions from the partners include RMB 70 million from the company, RMB 30 million from Taimei Zhiyan, RMB 100 million from Jiaxing Chantuo, and smaller amounts from individual partners [1] - The partnership enterprise will primarily invest in companies located in the Jiaxing Economic and Technological Development Zone [1] Group 2 - The board believes that the establishment of the partnership enterprise will allow the company to deeply engage in the research and development of innovative drug pipelines [2] - The company aims to standardize and modularize its digital pharmaceutical R&D solutions for early to growth-stage innovative drug development pipelines, potentially sharing in the excess returns from successful drug development [2] - By holding pipeline rights through the partnership, the company can participate in early clinical trials, thus avoiding the complexities and long-term risks associated with traditional equity investments [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任 何 損 失 承 擔 任 何 責 任。 Zhejiang Taimei Medical Technology Co., Ltd. 浙江太美醫療科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：2576） 須予披露交易 成立合夥企業 成立合夥企業 於2025年12月24日（交 易 時 段 後），本 公 司（作 為 有 限 合 夥 人）、太 美 智 研 （作 為 有 限 合 夥 人）、嘉 興 產 投（作 為 有 限 合 夥 人）、陸 高 峰 先 生（作 為 有 限 合 夥 人）、陸 海 嘯 女 士（作 為 有 限 合 夥 人）、陳 國 娟 女 士（作 為 有 限 合 夥 人）及 凱 風 太 美（作 為 普 通 合 夥 人）訂 立 合 夥 企 業 協 議，內 容 有 關 成 立 合 夥 企 業。所 有 合 夥 人 向 ...

根据IDC中国最新发布的2024年中国临床试验信息系统市占率报告——《中国临床试验信息系统市场份 额，2024：智能化驱动市场增长》显示，2024年太美医疗科技在中国临床试验信息系统市场份额排名第 一，这是太美医疗科技连续第4年位居该榜单首位。 未来，太美医疗科技将继续秉持"释放数智化力量，让健康触手可及"的企业愿景，持续加码核心技术研 发，进一步强化在技术创新、产品迭代与服务升级上的领先优势，加快构建服务未来的下一代医药产业 数智化基础设施，以数智力量驱动产业变革，助力我国医药产业核心竞争力提升，为促进医药产业高质 量发展贡献更多力量。 此次遴选重点考察企业专业化发展水平、核心技术创新能力、市场竞争力及质量效益，要求入选企业具 备生产技术或工艺水平领先、单项产品市场占有率位居行业前列等核心特质，兼具典型性、示范性与引 领性；遴选范围涵生物医药、信息科技、汽车制造、能源存储等多个关键产业。 Trials智能临床研究协作平台由太美医疗科技自主研发，以协作为核心理念，整合临床研究全系列数智 化解决方案，AI全流程赋能，实现临床研究复杂多方的跨组织在线协作，显著提升医药研发整体效 率，加速研究周期，降低研究成本。 ...